Nuvalent (NUVL) Current Assets (2020 - 2026)
Nuvalent's (NUVL) quarterly Current Assets came in at $1.3 billion in Q1 2026, up 20.37% YoY from $1.1 billion in Q1 2025, and down 6.07% on a QoQ basis from $1.4 billion in Q4 2025.
Nuvalent (NUVL) Current Assets (2020 - 2026) Analysis & Trends
Nuvalent (NUVL) has 7 years of Current Assets data on file, last reported at $1.3 billion in Q1 2026.
- Quarterly Current Assets rose 20.37% year-over-year to $1.3 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 billion (up 20.37% YoY) and the FY2025 annual result came in at $1.4 billion, up 22.96% from the prior year.
- Current Assets declined to $1.3 billion in Q1 2026, from $1.4 billion in the prior quarter.
- In the past five years, Current Assets ranged from a high of $1.4 billion in Q4 2025 to a low of $245.2 million in Q3 2022.
- A 5-year average of $749.3 million and a median of $699.5 million in 2024 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2022 — Current Assets fell 19.63% — and 2024, when it surged 181.03%.
- Tracing NUVL's Current Assets over 5 years: stood at $478.0 million in 2022, then jumped by 51.99% to $726.5 million in 2023, then jumped by 55.88% to $1.1 billion in 2024, then increased by 22.96% to $1.4 billion in 2025, then declined by 6.07% to $1.3 billion in 2026.
- The last three Current Assets figures came in at $1.3 billion (Q1 2026), $1.4 billion (Q4 2025), and $956.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Nuvalent | 9.10 Bn | 9.10 Bn | - | 1.31 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.31 Bn |
| Dec 31, 2025 | 1.39 Bn |
| Sep 30, 2025 | 956.95 Mn |
| Jun 30, 2025 | 1.02 Bn |
| Mar 31, 2025 | 1.09 Bn |
| Dec 31, 2024 | 1.13 Bn |
| Sep 30, 2024 | 1.18 Bn |
| Jun 30, 2024 | 666.26 Mn |
| Mar 31, 2024 | 699.49 Mn |
| Dec 31, 2023 | 726.49 Mn |
| Sep 30, 2023 | 419.77 Mn |
| Jun 30, 2023 | 436.99 Mn |
| Mar 31, 2023 | 456.29 Mn |
| Dec 31, 2022 | 477.99 Mn |
| Sep 30, 2022 | 245.25 Mn |
| Jun 30, 2022 | 258.82 Mn |
| Mar 31, 2022 | 274.47 Mn |
| Dec 31, 2021 | 290.63 Mn |
| Sep 30, 2021 | 305.14 Mn |
| Jun 30, 2021 | 139.28 Mn |